SG11201503505QA - Novel orally bioavailable breathing control modulating compounds, and methods of using same - Google Patents

Novel orally bioavailable breathing control modulating compounds, and methods of using same

Info

Publication number
SG11201503505QA
SG11201503505QA SG11201503505QA SG11201503505QA SG11201503505QA SG 11201503505Q A SG11201503505Q A SG 11201503505QA SG 11201503505Q A SG11201503505Q A SG 11201503505QA SG 11201503505Q A SG11201503505Q A SG 11201503505QA SG 11201503505Q A SG11201503505Q A SG 11201503505QA
Authority
SG
Singapore
Prior art keywords
methods
same
modulating compounds
orally bioavailable
breathing control
Prior art date
Application number
SG11201503505QA
Inventor
James C Mannion
Scott L Dax
Francis John Golder
Duncan Euan Macintyre
James Mcleod
Vita Ozola
Edgars Suna
Kirill Shubin
James Joseph Mencel
Sean X Peng
Original Assignee
Galleon Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Galleon Pharmaceuticals Inc filed Critical Galleon Pharmaceuticals Inc
Publication of SG11201503505QA publication Critical patent/SG11201503505QA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00Anaesthetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D251/00Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D251/26Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hetero atoms directly attached to ring carbon atoms
    • C07D251/40Nitrogen atoms
    • C07D251/54Three nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D251/00Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D251/26Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hetero atoms directly attached to ring carbon atoms
    • C07D251/40Nitrogen atoms
    • C07D251/54Three nitrogen atoms
    • C07D251/70Other substituted melamines
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D473/00Heterocyclic compounds containing purine ring systems
    • C07D473/02Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/16Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two nitrogen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Anesthesiology (AREA)
  • Psychiatry (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Psychology (AREA)
  • Vascular Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Otolaryngology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
SG11201503505QA 2012-11-15 2013-11-14 Novel orally bioavailable breathing control modulating compounds, and methods of using same SG11201503505QA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261726823P 2012-11-15 2012-11-15
US201361783451P 2013-03-14 2013-03-14
PCT/US2013/070160 WO2014078575A2 (en) 2012-11-15 2013-11-14 Novel orally bioavailable breathing control modulating compounds, and methods of using same

Publications (1)

Publication Number Publication Date
SG11201503505QA true SG11201503505QA (en) 2015-06-29

Family

ID=50731822

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201503505QA SG11201503505QA (en) 2012-11-15 2013-11-14 Novel orally bioavailable breathing control modulating compounds, and methods of using same

Country Status (12)

Country Link
US (1) US20150291597A1 (en)
EP (1) EP2920155A2 (en)
JP (1) JP2015537032A (en)
KR (1) KR20150082633A (en)
CN (1) CN104918923A (en)
AU (1) AU2013344653A1 (en)
BR (1) BR112015011213A2 (en)
CA (1) CA2891342A1 (en)
EA (1) EA201590933A1 (en)
MX (1) MX2015006120A (en)
SG (1) SG11201503505QA (en)
WO (1) WO2014078575A2 (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2013267570A1 (en) * 2012-05-29 2014-12-18 Galleon Pharmaceuticals, Inc. Novel compounds and compositions for treatment of breathing control disorders or diseases
US9549909B2 (en) 2013-05-03 2017-01-24 The Katholieke Universiteit Leuven Method for the treatment of dravet syndrome
US10004749B2 (en) 2015-07-22 2018-06-26 John Hsu Composition comprising a therapeutic agent and a respiratory stimulant and methods for the use thereof
EP3393470B1 (en) 2015-12-22 2021-01-20 Zogenix International Limited Metabolism resistant fenfluramine analogs and methods of using the same
RU2731179C2 (en) 2015-12-22 2020-08-31 Зодженикс Интернэшнл Лимитед Fenfluramine compositions and methods for production thereof
JP2019526544A (en) 2016-08-24 2019-09-19 ゾゲニクス インターナショナル リミテッド Formulations for inhibiting the formation of 5-HT2B agonists and methods of use thereof
US10682317B2 (en) 2017-09-26 2020-06-16 Zogenix International Limited Ketogenic diet compatible fenfluramine formulation
US11571397B2 (en) 2018-05-11 2023-02-07 Zogenix International Limited Compositions and methods for treating seizure-induced sudden death
WO2019241005A1 (en) 2018-06-14 2019-12-19 Zogenix International Limited Compositions and methods for treating respiratory depression with fenfluramine
US11612574B2 (en) 2020-07-17 2023-03-28 Zogenix International Limited Method of treating patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
US20230140606A1 (en) * 2021-11-02 2023-05-04 Enalare Therapeutics Inc. Methods of treating respiratory depression modulated by a non-opioid agent
WO2023129502A1 (en) * 2021-12-27 2023-07-06 Enalare Therapeutics Inc. Respiratory stimulant parenteral formulations

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9106170D0 (en) * 1991-03-22 1991-05-08 Jarman Michael New compounds for use in the treatment of cancer
JP5249042B2 (en) * 2006-10-30 2013-07-31 新日鉄住金化学株式会社 Proton conducting compound and proton conducting polymer
DE102007025451B4 (en) * 2007-05-31 2013-03-28 Ami Agrolinz Melamine International Gmbh triazine derivatives
SG10201601507YA (en) * 2010-11-29 2016-04-28 Galleon Pharmaceuticals Inc Novel compounds as respiratory stimulants for treatment of breathing control disorders or diseases
WO2012166909A1 (en) * 2011-06-03 2012-12-06 Galleon Pharmaceuticals, Inc. Compositions and methods for treating breathing control disorders or diseases

Also Published As

Publication number Publication date
CN104918923A (en) 2015-09-16
BR112015011213A2 (en) 2017-08-29
US20150291597A1 (en) 2015-10-15
CA2891342A1 (en) 2014-05-22
WO2014078575A3 (en) 2014-10-16
AU2013344653A1 (en) 2015-05-21
KR20150082633A (en) 2015-07-15
MX2015006120A (en) 2016-02-05
WO2014078575A2 (en) 2014-05-22
EA201590933A1 (en) 2015-11-30
EP2920155A2 (en) 2015-09-23
JP2015537032A (en) 2015-12-24

Similar Documents

Publication Publication Date Title
SG11201503505QA (en) Novel orally bioavailable breathing control modulating compounds, and methods of using same
GB2500583B (en) Interference control
WO2013158208A9 (en) Multi-modal synchronization therapy
EP2922615A4 (en) Control of mercury emissions
SG11201502932TA (en) Compounds and methods for the production of suckerin and uses thereof
EP2935226A4 (en) Heteroaryl compounds and uses thereof
EP2867209A4 (en) Compounds and therapeutic uses thereof
HK1202991A1 (en) Control transformer
ZA201504167B (en) Processes for the preparation of 4-amino-3-halo-6- (substituted)picolinates and 4-amino-5-fluoro-3-halo-6- (substituted)picolinates
HK1219234A1 (en) Novel breathing control modulating compounds, and methods of using same
PL2882708T3 (en) New compounds and uses thereof
TWI562792B (en) Breathing apparatus
EP2804612A4 (en) Therapeutic uses of tetrachlorodecaoxygen (tcdo)
GB2519926B (en) Breathing apparatus
HUE036419T2 (en) Treatment of respiratory depression
GB201203391D0 (en) Medico-surgical assemblies
AU2012904536A0 (en) Improved breathing apparatus
AU2012903663A0 (en) Improved breathing apparatus
AU2012902308A0 (en) Breathing Means
GB2499018B (en) Breathing mask
AU2012904991A0 (en) Therapeutic Compounds and Uses Thereof
HK1170109A2 (en) Red cheque packet
GB201216381D0 (en) New compounds and medical uses
GB201208970D0 (en) New compounds and medical uses
GB201203388D0 (en) Medico-surgical assemblies